{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:59:49Z","timestamp":1780066789339,"version":"3.54.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005064","name":"Hebei Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["17272604D"],"award-info":[{"award-number":["17272604D"]}],"id":[{"id":"10.13039\/501100005064","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anthracyclines have a profound effect on breast cancer. However, at higher dosages, there are many toxic side effects associated with their use; these include bone marrow suppression, alopecia, gastrointestinal reactions and cardiotoxicity. Pegylated liposomal doxorubicin (PEG-LG) has been demonstrated to achieve equivalent efficacy to conventional doxorubicin, with significantly lower cardiotoxicity. We conducted an open-label, multicenter, single-armed clinical trial useing an NAC regimen based on four cycles of PEG-LD 40\u2009mg\/m<jats:sup>2<\/jats:sup> plus cyclophosphamide (CPM) 600\u2009mg\/m<jats:sup>2<\/jats:sup> on day 1 of a 21 day schedule, followed by four cycles of docetaxel (DTX) 85\u2009mg\/m<jats:sup>2<\/jats:sup> on day 1 of a 21 day schedule. The primary endpoint analysed was the pathological complete response rate (pCR) in the breast, while treatment toxicities and safety were also assessed. The results showed that the breast pCR rate was 18.75% (95% CI 11.5\u201326.0%). Among the different molecular cancer types, the triple negative breast cancer patients had the highest pCR, at 43.75%. No significant decrease in left ventricular ejection fraction was observed. Our data tends to draw the conclusion that this regimen is a viable option for the neoadjuvant treatment of patients with LABC, especially in the triple-negative subtype and patients with heart abnormalities. We believe the efficacy and the safety of this regimen is likely to be the same based on published data from other studies but that this cannot be certain without a randomized trial.<\/jats:p>","DOI":"10.1038\/s41598-019-54387-5","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T11:37:14Z","timestamp":1575286634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052)"],"prefix":"10.1038","volume":"9","author":[{"given":"Ruoyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuguo","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianli","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenchuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"54387_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA Cancer J Clin. 66, 7\u201330 (2016).","journal-title":"CA Cancer J Clin."},{"key":"54387_CR2","first-page":"1996","volume":"49","author":"B Fisher","year":"1989","unstructured":"Fisher, B., Gunduz, N., Coyle, J., Rudock, C. & Saffer, E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 49, 1996\u20132001 (1989).","journal-title":"Cancer Res."},{"key":"54387_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019s Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019s Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 365, 1687\u2013171 (2005).","journal-title":"Lancet."},{"key":"54387_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi, P. et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 26, 778\u2013785 (2008).","journal-title":"J Clin Oncol."},{"key":"54387_CR5","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1200\/JCO.2004.03.516","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez, E. A. et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 22, 3700\u20133704 (2004).","journal-title":"J Clin Oncol."},{"key":"54387_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff, D. D. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 91, 710\u2013717 (1979).","journal-title":"Ann Intern Med."},{"key":"54387_CR7","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1200\/JCO.2005.02.5841","volume":"23","author":"JJ Doyle","year":"2005","unstructured":"Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R. & Hershman, D. L. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 23, 8597\u20138605 (2005).","journal-title":"J Clin Oncol."},{"key":"54387_CR8","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1002\/cncr.24621","volume":"115","author":"XL Du","year":"2009","unstructured":"Du, X. L. et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 115, 6296\u20135308 (2009).","journal-title":"Cancer."},{"key":"54387_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3816\/CBC.2003.n.037","volume":"4","author":"JA O\u2019 Shaughnessy","year":"2003","unstructured":"O\u2019 Shaughnessy, J. A. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer. 4, 318\u2013328 (2003).","journal-title":"Clin Breast Cancer."},{"key":"54387_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien, M. E. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 15, 440\u2013449 (2004).","journal-title":"Ann Oncol."},{"key":"54387_CR11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","volume":"89","author":"O Lyass","year":"2000","unstructured":"Lyass, O. et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin in metastatic breast carcinoma. Cancer. 89, 1037\u20131040 (2000).","journal-title":"Cancer."},{"key":"54387_CR12","first-page":"987","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon, A. et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987\u2013992 (1994).","journal-title":"Cancer Res."},{"key":"54387_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000498993","volume":"3","author":"M Cheng","year":"2019","unstructured":"Cheng, M. et al. A dose-escalating pilot study (NCT03017404) of pegylated liposomal doxorubicin and cyclophosphamide, followed by docetaxel administration as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer. Oncol Res Trea. 3, 1\u20136, https:\/\/doi.org\/10.1159\/000498993 (2019).","journal-title":"Oncol Res Trea."},{"key":"54387_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45, 228\u2013247 (2009).","journal-title":"Eur J Cancer."},{"key":"54387_CR15","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1200\/JCO.2004.02.122","volume":"22","author":"V Dieras","year":"2004","unstructured":"Dieras, V. et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol. 22, 4958\u20134965 (2004).","journal-title":"J Clin Oncol."},{"key":"54387_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.23544","volume":"113","author":"F Cuppone","year":"2008","unstructured":"Cuppone, F. et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer. 113, 238\u2013246 (2008).","journal-title":"Cancer."},{"key":"54387_CR17","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/JCO.2005.06.156","volume":"23","author":"TR Evans","year":"2005","unstructured":"Evans, T. R. et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol. 23, 2988\u20132995 (2005).","journal-title":"J Clin Oncol."},{"key":"54387_CR18","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","volume":"24","author":"HD Bear","year":"2006","unstructured":"Bear, H. D. et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 24, 2019\u20132027 (2006).","journal-title":"J Clin Oncol."},{"key":"54387_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-015-3415-2","volume":"151","author":"J Miguel","year":"2015","unstructured":"Miguel, J. & Gil-Gil, C. Mesia1. Pegylated liposomal doxorubicin plus cycloph-osphamide followed by paclitaxel as primary chemotherapy in elderly or cardio-toxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 151, 597\u2013606 (2015).","journal-title":"Breast Cancer Res Treat."},{"key":"54387_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1200\/JCO.2001.19.1.37","volume":"19","author":"M Zambetti","year":"2001","unstructured":"Zambetti, M. et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol. 19, 37\u201343 (2001).","journal-title":"J Clin Oncol."},{"issue":"1","key":"54387_CR21","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/j.clbc.2017.10.005","volume":"18","author":"Amy E. Chang","year":"2018","unstructured":"Chang, A. E., Wu, Q. V. Phase I\/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. Clin Breast Cancer. 18(1), e143\u2013e149, https:\/\/doi.org\/10.1016\/j.clbc.2017.10.005, Epub 2017 Oct 9 (2018).","journal-title":"Clinical Breast Cancer"},{"key":"54387_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1433-4","volume":"15","author":"K-M Rau","year":"2015","unstructured":"Rau, K.-M., Lin, Y.-C. & Chen, Y.-Y. Pegylated liposomal doxorubicin (LipoDox) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study. BMC Cancer. 15, 423 (2015).","journal-title":"BMC Cancer."},{"key":"54387_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdu551","volume":"26","author":"H Bonnefoi","year":"2015","unstructured":"Bonnefoi, H. et al. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2positive breast cancer: results of the randomized phase II UEPRTC 10054 study. Ann Oncol. 26, 325\u2013332 (2015).","journal-title":"Ann Oncol."},{"key":"54387_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1631\/jzus.B1600303","volume":"18","author":"M Zhao","year":"2017","unstructured":"Zhao, M., Ding, X. F. & Shen, J. Y. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice. J Zhejiang Univ Sci B. 18, 15\u201326 (2017).","journal-title":"J Zhejiang Univ Sci B."},{"key":"54387_CR25","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.2147\/OTT.S162003","volume":"11","author":"M Dong","year":"2018","unstructured":"Dong, M. et al. Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study. Onco Targets Ther. 11, 4247\u20134252 (2018).","journal-title":"Onco Targets Ther."},{"key":"54387_CR26","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1093\/annonc\/mdf284","volume":"13","author":"H Gogas","year":"2002","unstructured":"Gogas, H. et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol. 13, 1737\u20131742 (2002).","journal-title":"Ann Oncol."},{"key":"54387_CR27","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1200\/JCO.2005.03.8331","volume":"24","author":"S Chia","year":"2006","unstructured":"Chia, S. et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 24, 2773\u20132777 (2006).","journal-title":"J Clin Oncol."},{"key":"54387_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/cgt.2017.9","volume":"24","author":"L Ansari","year":"2017","unstructured":"Ansari, L. et al. The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials. Cancer Gene Ther. 24, 189\u2013193 (2017).","journal-title":"Cancer Gene Ther."},{"key":"54387_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000093005","volume":"70","author":"SE Al-Batran","year":"2006","unstructured":"Al-Batran, S. E. et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg\/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 70, 141\u2013146 (2006).","journal-title":"Oncology."},{"key":"54387_CR30","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","volume":"16","author":"V Siband","year":"2011","unstructured":"Siband, V. et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist. 16, 1469\u20131478 (2011).","journal-title":"Oncologist."},{"key":"54387_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3816\/CBC.2005.n.017","volume":"2","author":"B Overmoyer","year":"2005","unstructured":"Overmoyer, B. et al. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer. 2, 150\u201315 (2005).","journal-title":"Clin Breast Cancer."},{"key":"54387_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/annonc\/mdt588","volume":"25","author":"CH Smorenburg","year":"2014","unstructured":"Smorenburg, C. H. et al. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol. 25, 599\u2013605 (2014).","journal-title":"Ann Oncol."},{"key":"54387_CR33","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/annonc\/mdr024","volume":"22","author":"M Mart\u00edn","year":"2011","unstructured":"Mart\u00edn, M. et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM\/2004\u201305 study. Ann Oncol. 22, 2591\u20132596 (2011).","journal-title":"Ann Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54387-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:53:11Z","timestamp":1671295991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54387-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54387"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54387-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]},"assertion":[{"value":"19 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18135"}}